3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Cytarabine
184
Cyclophosphamide
176
fludarabine
146
Azacitidine
121
venetoclax
115
fludarabine phosphate
104
Rituximab
80
Decitabine
74
Filgrastim
58
Specimen Handling
55
Etoposide
55
Lenalidomide
47
Biopsy
45
Dexamethasone
41
Methotrexate
40
Bortezomib
40
Mitoxantrone
39
Granulocyte Colony-Stimulating Factor
39
Daunorubicin
39
Vincristine
37
Melphalan
36
ibrutinib
35
Tacrolimus
35
Dasatinib
34
Whole-Body Irradiation
32
Clofarabine
32
Peripheral Blood Stem Cell Transplantation
31
Mycophenolic Acid
31
Injections
31
Idarubicin
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
bemcentinib
×
Other hematologic neoplasm
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts